Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2020 / Articles / Dec / Pandemic Preparedness
Manufacture Vaccines COVID-19

Pandemic Preparedness

What have we learned from the pandemics of the past? Experts give their view in a video discussion

12/16/2020 1 min read

Share

Why was the world so unprepared for a coronavirus pandemic? Long before 2020, scientific experts, the WHO, and even the World Bank pointed out that coronaviruses could be problematic. In some ways, we were perhaps lulled into a false sense of security by recent epidemics and pandemics. SARS and MERS did not spread extensively across the globe, and the 2009 H1N1 crisis was considered mild in comparison to 1918’s Spanish flu.

“We took our eye off the ball – possibly in 2008 when funding for betacoronaviridae took a nosedive because we went into an economic crash,” says Adrian Wildfire, Director, Scientific and Business Strategy at hVIVO, a clinical development services business.

Wildfire recently moderated a roundtable discussion for The Medicine Maker focusing on how previous pandemics have shaped responses to the COVID-19 crisis. The conversation involved Pieter Neels, Chair of the Human Vaccine Committee of the International Alliance for Biological Standardization; Marco Cavaleri, Head of Office, Biological Health Threats and vaccines strategy at EMA; Rebecca Cox, Professor of Medical Virology and Head of the Influenza Centre at the University of Bergen and Haukeland University Hospital, Norway; and Daniel Hoft, Professor of Internal Medicine at St Louis University School of Medicine, USA.

“We were not prepared because the revious SARS and MERS pandemics were far from our bedside,” said Neels. “The 2 0 0 9 H 1 N 1 crisis was judged a mild influenza, so why should we have all these measures in place for such a pandemic?” As an example of complacency, before the COVID-19 crisis broke out, Belgium destroyed a strategic stockpile of millions of masks because it didn’t think they would be needed. The masks were purchased over a decade ago because of fears of an influenza epidemic. However, Neels adds that we “simply could not imagine that the next pandemic would be on the same level as the Spanish flu.”

But it’s not all bad news. When it comes to vaccine manufacture, processes have certainly changed drastically over the last century – emphasized by the fact that the industry has been able to create new vaccines for COVID-19 in such a short space of time.

Wildfire, Neels, and the other participants discuss these topics and more in the video roundtable.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

Recommended

False

Related Content

Understanding the H5N1 Threat
Vaccines Drug Discovery
Understanding the H5N1 Threat

February 3, 2025

4 min read

With new cases of avian influenza appearing, what does this mean for global health and what are drug developers doing about it?

Peter Marks Resigns from FDA
Standards & Regulation Profession Vaccines Advanced Medicine
Peter Marks Resigns from FDA

April 1, 2025

3 min read

Resignation letter states: “truth and transparency” around vaccines are not desired by Health Secretary RJK Jr. “Rather he wishes subservient confirmation of his misinformation and lies.”

The Shingles Vaccine and Dementia
Drug Discovery Translational Science Vaccines
The Shingles Vaccine and Dementia

April 10, 2025

2 min read

Studies have suggested that the RZV shingles vaccine can lower the risk of dementia; GSK is now investigating further

Robert F. Kennedy Jr Nomination Advances
Standards & Regulation Vaccines
Robert F. Kennedy Jr Nomination Advances

February 6, 2025

2 min read

Senate committee votes in favor of the nomination; full Senate vote will be next

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.